Kiora Pharmaceuticals (KPRX) News
NASDAQ: KPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.7202-0.1008 (-12.28%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KPRX news summary
We found 2 recent headlines mentioning Kiora Pharmaceuticals (KPRX): 0 in the past week and 2 in the past 30 days, most often from Nasdaq. KPRX is making an outsized move today, down 12.28% at $0.7202, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and KIO-401 In-Licensing", was published by Nasdaq on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Kiora Pharmaceuticals headlines
- Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and KIO-401 In-LicensingKiora Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighted by the in-licensing of KIO-401 (mitucapistat)…Nasdaq
- Kiora Pharmaceuticals, Inc. Enters Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. for KIO-401On October 23, 2026, Kiora Pharmaceuticals, Inc. entered into an Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. to license a late-stage neuroprotective, oral small-molecule calpain…Nasdaq